Distal jejunal-release dextrose beads-Aphaia Pharma
Alternative Names: APH-012; APHD-006; APHD-008; APHD-012Latest Information Update: 24 Jun 2024
Price :
$50 *
At a glance
- Originator Aphaia Pharma
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Prediabetic state
Most Recent Events
- 20 Jun 2024 Efficacy, pharmacokinetics and adverse event data from a phase II trial in Prediabetic state released by Aphaia Pharma
- 13 Feb 2024 Aphaia Pharma completes the phase-II trial in Prediabetic state in Slovakia (PO, Granules) (EudraCT 2022-003205-29) (NCT05803772)
- 25 Apr 2023 Phase-I clinical trials in Prediabetic state in unknown location (PO)